Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IcoCell

Financiado

Cerrado

Cell line development platform for SMEs to reduce the length and cost of biologi...

Cell line development platform for SMEs to reduce the length and cost of biologic drug development Biologic drugs ($160+ billion market) provide better long-term health outcomes with fewer side effects than many traditional drugs. However, due to high development and production costs, these drugs are 20x more expensive, on aver... ver más

31/08/2018

ICOSAGEN CELL FACT...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

ICOSAGEN CELL FACTORY OU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-08-31

BIOTEC-5b-2015: SME boosting biotechnology-based in...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ICOSAGEN CELL FACTORY LTD

1.13M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

HOLOCELL Holographic Assembler for 3D Cell Cultures 150K€ Cerrado

SECReTE Enhancing biological drug production through protein secreti... 150K€ Cerrado

Facer The First Cell Culture Platform that Enables Affordable Cell... 2M€ Cerrado

FUTURE-PHARMA Exploiting plants for the production of future generation re... 3M€ Cerrado

Kyron.bio WomenTech Cell line engineering for imporved fertility treatment 75K€ Cerrado

MATERIAS PRIMAS FARMACÉUTICAS OBTENIDAS MEDIA... MATERIAS PRIMAS FARMACÉUTICAS OBTENIDAS MEDIANTE TÉCNICAS DE... 745K€ Cerrado

Duración del proyecto: 28 meses Fecha Inicio: 2016-04-05
Fecha Fin: 2018-08-31

Líder del proyecto

ICOSAGEN CELL FACTORY OU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Biologic drugs ($160+ billion market) provide better long-term health outcomes with fewer side effects than many traditional drugs. However, due to high development and production costs, these drugs are 20x more expensive, on average, limiting the access to these therapies and burdening healthcare systems. To a great extent, this is because traditionally flexible and creative biotech SMEs currently lack rational tools for mammalian cell line development (most of the biologic drugs are produced in mammalian cell lines), meaning that large investment in terms of capital and time is required to make a production cell line. ICF, an established player in the biotechnology industry, develops a technology for more efficient development of mammalian cell lines for high-yield protein production. It reduces the need for robotic systems and high-throughput screening facilities (€900 000 -> €200 000), the time (6-12 months -> 3) and cost (€100 000 -> €50 000) of cell line development. These advantages stem from specific landing platforms, predefined integration sites, recombination-dependent insertion and amplification of expression units. The technology will enable biotech SMEs to develop the process of production of new biologic drugs at lower costs and faster, eventually enabling biologic drugs to penetrate more cost-sensitive indications and target groups. IcoCell project is aimed at optimizing the landing platform, generating cell lines compatible with process of development of industrial cell factories, generating regulatory documentation, preparing standard operating procedures, demonstrating the production of different types of proteins and implementing initial exploitation activities. Cell line development market is expected to grow at CAGR of 12.8% (2014-2022) and the market for cell line development to produce therapeutic proteins exceeds €900M. Commercialization of IcoCell technology will mean breakthrough for ICF, increasing revenues by an estimated €26M in 2021

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores